Silo Pharma (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the company's common stock. The program allows purchases on the open market, through privately negotiated transactions, or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements. As of November 13, 2025, the company reported 13,318,273 shares of common stock outstanding, according to its quarterly report for the period ended September 30, 2025.
The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations. The program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion. This move signals management's belief that the company's stock is undervalued and aims to enhance shareholder value.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
The share repurchase authorization comes as the company continues to advance its pipeline and manage its crypto treasury strategy. For more details, the full press release can be viewed at https://ibn.fm/gU3uZ. Investors can also find the latest news and updates relating to SILO in the company's newsroom at https://ibn.fm/SILO.
The repurchase program reflects a commitment to deploying capital efficiently while maintaining flexibility for future growth initiatives. It underscores the board's confidence in the company's strategic direction and long-term prospects. Silo Pharma continues to focus on developing therapies for underserved medical conditions and managing its cryptocurrency treasury to support operations and potential acquisitions.
This announcement is important because it provides a floor for the stock price and demonstrates insider confidence at a time when many biotech stocks face volatility. Share repurchases can also be a tax-efficient method of returning value to shareholders.
